Trial Profile
A Phase II Trial of Panitumumab, Gemcitabine, and Carboplatin in Triple-Negative Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Gemcitabine (Primary) ; Panitumumab (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 14 Dec 2014 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 10 Sep 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 09 Jul 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.